利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

229 条记录 (耗时 0.021 秒)

    IN VIVO INDUCED TOXOPLASMA GONDII PROTEIN FOR APPLICATION IN DIAGNOSIS, VACCINE AND THERAPY
    5.
    发明申请
    IN VIVO INDUCED TOXOPLASMA GONDII PROTEIN FOR APPLICATION IN DIAGNOSIS, VACCINE AND THERAPY 审中-公开
    用于诊断，疫苗和治疗的VIVO诱导的ToxopLASMA GONDII蛋白

    公开(公告)号：WO2016059502A1

    公开(公告)日：2016-04-21

    申请号：PCT/IB2015/057522

    申请日：2015-10-01

    申请人： UNIVERSITI SAINS MALAYSIA

    发明人： NOORDIN, Rahmah Binti ,  AMERIZADEH, Atefeh

    IPC分类号： C07K14/45 ,  A61K39/002 ,  C12N15/30 ,  G01N33/53

    CPC分类号： G01N33/56905 ,  A61K39/002 ,  C07K14/45 ,  G01N2333/45 ,  G01N2469/20

    摘要： The present invention relates to methods of screening biological samples for the presence of T. gondii. More particularly, the present invention relates to a sensitive and specific screening test for the presence of Toxoplasmosis in subjects by using or detecting the in vivo-induced T. gondii RAP domain binding protein antigen. The invention further relates to the use of the in vivo-induced antigen in the prevention or therapy of Toxoplasmosis.

    摘要翻译： 本发明涉及筛选生物样品用于存在弓形虫的方法。 更具体地，本发明涉及通过使用或检测体内诱导的弓形虫RAP结构域结合蛋白抗原来检测受试者中弓形虫病的敏感和特异性筛选试验。 本发明还涉及体内诱导的抗原在预防或治疗弓形体病中的应用。

    GENE MODIFICADO DE LEISHMANIA SSP., PROCESSO PARA OBTENÇÃO DE PROTEÍNA E USO COMO ANTÍGENO EM COMPOSIÇÃO VACINAL OU EM IMUNODIAGNÓSTICO
    6.
    发明申请
    GENE MODIFICADO DE LEISHMANIA SSP., PROCESSO PARA OBTENÇÃO DE PROTEÍNA E USO COMO ANTÍGENO EM COMPOSIÇÃO VACINAL OU EM IMUNODIAGNÓSTICO 审中-公开
    来自LEISHMANIA SSP的改良基因，生产蛋白质的方法和用作疫苗组合物或免疫测定中的抗原

    公开(公告)号：WO2015029002A1

    公开(公告)日：2015-03-05

    申请号：PCT/IB2014/064203

    申请日：2014-09-02

    申请人： UNIVERSIDADE FEDERAL DE MINAS GERAIS - UFMG

    发明人： SALLES MOURA FERNANDES, Ana Paula ,  TOSTES GAZZINELLI, Ricardo ,  MIRANDA DAMASCENO, Leonardo

    IPC分类号： C12N15/09 ,  C12N15/11 ,  C12N15/30 ,  A61K39/00 ,  A61K39/008

    CPC分类号： C07K14/44 ,  A61K39/008 ,  A61K2039/57

    摘要： A presente invenção descreve uma sequência nucleotídica resultante da modificação e redução do gene que codifica a proteína A2 de Leishmania, bem como seu processo de obtenção e seus usos e uma composição vacinal contendo a proteína obtida a partir deste gene modificado. As modificações introduzidas viabilizam a execução mais eficiente de técnicas de Biologia Molecular, como PCR, clonagem e expressão heteróloga, bem como permitem a expressão da proteína A2HIS-OZ em células procarióticas com maior rendimento. Esses aspectos são especialmente interessantes para o controle de qualidade e produção da proteína em escala industrial. A proteína A2HIS-OZ obtida a partir deste gene modificado poderá ser utilizada como antígeno vacinal na prevenção de leishmaniose canina ou humana ou como antígeno para imunodiagnóstico da leishmaniose visceral.

    摘要翻译： 本发明描述由编码利什曼原虫蛋白A2的基因的修饰和还原产生的核苷酸序列及其制备方法及其用途，以及含有由所述修饰基因产生的蛋白质的疫苗组合物。 所引入的修饰使得能够更有效地使用分子生物学技术，例如PCR，克隆和异源表达，并且允许在原核细胞中以更高的产量表达A2HIS-OZ蛋白。 这些方面对于控制工业规模的蛋白质的质量和生产是特别有意义的。 由所述修饰基因产生的A2HIS-OZ蛋白可用作预防犬或人利什曼病的疫苗抗原，或作为内脏利什曼病免疫诊断的抗原。

    CONSTRUCTING A DNA CHIMERA FOR VACCINE DEVELOPMENT AGAINST LEISHMANIASIS AND TUBERCULOSIS
    9.
    发明申请
    CONSTRUCTING A DNA CHIMERA FOR VACCINE DEVELOPMENT AGAINST LEISHMANIASIS AND TUBERCULOSIS 审中-公开
    构建DNA疫苗，用于疫苗发生和淋巴细胞增殖

    公开(公告)号：WO2010010577A1

    公开(公告)日：2010-01-28

    申请号：PCT/IN2009/000093

    申请日：2009-02-10

    申请人： DEPARTMENT OF BIOTECHNOLOGY ,  ALL INDIA INSTITUTE OF MEDICAL SCIENCE ,  SINGH, Sarman ,  DEY, Ayan

    发明人： SINGH, Sarman ,  DEY, Ayan

    IPC分类号： A61K39/04 ,  A61K39/008 ,  C12N15/31 ,  C12N15/30

    CPC分类号： C07K14/35 ,  A61K39/00 ,  A61K2039/53 ,  C07K14/44 ,  Y02A50/41

    摘要： This invention relates to a novel recombinant chimera of DNA construct having esat-6 region of Mycobacterium tuberculosis and kinesin region of Leishmania donovani cloned together on two sides of self cleaving peptide in a DNA vaccine vector pVAX-1 wherein the Chimeric construct is operatively linked to a transcriptional promoter thus capable of self replication and expression within the mammalian cell and the process of preparation thereof comprising. Analysis of the predicted protein sequence of kinesin motor domain and esat-6 domain using Promiscuous MHC Class-1 Binding Peptide Prediction Servers. Amplification of gene coding for kinesin motor domain and esat-6 domain. Cloning of kinesin esat-6 gene region in pGEM-T® vector for sequence analysis. Generation of Chimeric construct by directional cloning in pVAX-1 vector. In-vitro expression analysis of kenesin motor domain and esat-6 domain from the clones using cell free translation system and immunogenicity studies, Splenocyte proliferative and cytokines studies using the above mentioned constructs.

    摘要翻译： 本发明涉及在DNA疫苗载体pVAX-1中克隆在自切割肽两侧的克隆在结核分枝杆菌的结核分枝杆菌esat-6区域和利什曼原虫驱动蛋白区域的新型重组嵌合体，其中嵌合构建体可操作地连接到 因此能够在哺乳动物细胞内自我复制和表达的转录启动子及其制备方法包括。 使用混杂MHC Class-1结合肽预测服务器分析驱动蛋白运动结构域和esat-6结构域的预测蛋白质序列。 扩增驱动蛋白运动区和esat-6结构域的基因编码。 在pGEM-T载体中克隆驱动蛋白esat-6基因区域用于序列分析。 通过在pVAX-1载体中定向克隆产生嵌合构建体。 使用无细胞翻译系统和免疫原性研究，使用上述构建体的脾细胞增殖和细胞因子研究，来自克隆的克隆中克隆运动区和esat-6结构域的体外表达分析。

    THEILERIA PARVA DNA VACCINES
    10.
    发明申请
    THEILERIA PARVA DNA VACCINES 审中-公开

    公开(公告)号：WO2006101810A3

    公开(公告)日：2006-09-28

    申请号：PCT/US2006/008981

    申请日：2006-03-10

    申请人： MERIAL LIMITED ,  AUDONNET, Jean-christophe, Francis ,  LOOSMORE, Sheena, May

    发明人： AUDONNET, Jean-christophe, Francis ,  LOOSMORE, Sheena, May

    IPC分类号： C12N15/30

    摘要： The present invention relates to recombinant anÍ-Theileria parva vaccines and the administration of such vaccines to animals, advantageously bovines. Advantageously, the anti-Theileria parva vaccine encompasses a recombinant avipox virus that includes a nucleotide sequence encoding a TheÊleria parva gene. The invention further relates to methods of vaccinating animals, advantageously bovines, by administration of anÍ-Theileria parva vaccines that may encompass a recombinant avipox virus that may contain a Theileria parva gene.